Amgen’s Stelara Biosimilar Produces Positive Phase III Results

Firm’s ABP 654 Ustekinumab Candidate Is Also Being Lined Up For Interchangeability

 
• By David Wallace
  
Amgen offices at Cambridge Science Park
Amgen has announced progress on its ustekinumab candidate • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products